EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an...
46 insider purchases on record · latest filing 2026-08-18.
Insiders have also filed 63 sale transactions at EYPT.